Krzowska-Firych Joanna, Przybyła Anna, Modrzewska Roma
Katedra i Klinika Chorób Zakaźnych Uniwersytetu Medycznego w Lublinie.
Przegl Epidemiol. 2009;63(3):383-6.
The aim of our study was to assess efficacy and safety of antiviral treatment with natural interferon alpha in patients with thrombocytopenia during chronic HCV infection. The study group consisted of 14 patients infected with HCV genotype lb. There were 8 women and 6 men (mean age 50). 11 of these had compensated liver cirrhosis. Three patients had previous reIFN or PegIFN alpha therapy with severe adverse events and lack of sustained viral response (SVR). Sustained viral response was achieved in 4 patients. Only in one case therapy was discontinued due to symptomatic hemorrhagic purpura.
我们研究的目的是评估天然α干扰素抗病毒治疗对慢性丙型肝炎病毒（HCV）感染伴血小板减少症患者的疗效和安全性。研究组由14例感染HCV 1b基因型的患者组成。其中有8名女性和6名男性（平均年龄50岁）。这些患者中有11例为代偿期肝硬化。3例患者既往接受重组干扰素（reIFN）或聚乙二醇化干扰素α（PegIFNα）治疗时出现严重不良事件且未获得持续病毒学应答（SVR）。4例患者获得了持续病毒学应答。仅1例因症状性出血性紫癜而停药。
